Welcome to your daily round-up of everything happening in the world of neurorehab.
Research
New AI algorithm detects rare epileptic seizures
USC researchers have developed an AI system to identify epilepsy by analysing brain interactions, improving diagnosis of rare and complex cases. The system, presented at the Advances in Knowledge Discovery and Data Mining (PAKDD) conference in May, demonstrated a 12 per cent improvement in state-of-the-art models.
Five minute test leads to better care for people with dementia
A new study finds that an easy, five-minute assessment paired with recommendations built into the electronic medical record system led to a three-fold improvement in diagnosis and treatment for patients in a primary care setting compared to a control group. The “5-Cog paradigm,” which was developed by researchers at Albert Einstein College of Medicine and Montefiore Health System, dramatically enhances the diagnosis of mild cognitive impairment and dementia, and represents a new, better way to guide initial treatment.
Injury prediction rule could decrease radiographic imaging exposure in children
In a new study researchers in the Pediatric Emergency Care Applied Research Network (PECARN) have created a highly accurate cervical spine injury prediction rule. When applied, the rule decreases the use of CT by more than 50 per cent without missing clinically significant injuries or increasing normal X-ray use.
Technology
New telehealth stroke certification for healthcare professionals
A new American Heart Association certification for healthcare professionals is designed to help standardise training and increase skills and competencies for health care providers in telehealth stroke care delivery, as well as help improve stroke outcomes through the integration of telehealth. This is the third individual certification available through the American Heart Association’s science-based certification portfolio.
Company updates
Zeto secures FDA approval for brain monitoring product
Zeto has announced that EEG brain monitoring product, ONE, has received clearance from the US Food and Drug Administration (FDA). ONE seamlessly streams data to the Zeto Cloud, enabling live remote interpretations by board-certified neurologists. In addition to its role as a point-of-care system, it serves as a comprehensive EEG platform, enabling various tasks such as workflow management, patient scheduling, and report generation.
Myrtelle gene therapy selected for FDA pilot programme
Myrtelle has announced that the FDA Center for Biologics Evaluation and Research (CBER) has selected the Company’s gene therapy, rAAV-Olig001-ASPA for the treatment of Canavan disease (CD), as one of a few programs for participation in the Support for Clinical Trials Advancing Rare Disease Therapeutics (START) Pilot Program. The objective of the program is to accelerate development of gene therapies for rare diseases that lead to significant disability or death within the first decade of life by facilitating more frequent advice and regular communication with FDA staff.
